Dr Reddy's launches oral bronchodilator for asthma, COPD
By Our Corporate Bureau | 16 May 2006
Doxofylline has been introduced under the brand name ‘Doxobid’ and the 400mg dosage will be available in a special pack of 10's. Doxobid is meant to treat patients suffering from asthma and/or chronic obstructive pulmonary disease (COPD).
Launched nationwide, Doxobid will further help the Dr Reddy's to consolidate its position in the asthma and COPD segment as it has been moving towards strengthening its respiratory portfolio. The total market of methyl xanthines (combinations and plain) is estimated at around at Rs 60 crore.